Close Menu

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray has upgraded its rating on Genomic Health's stock to overweight, maintaining a price target for shares of $72, based on an assessment of the current pace of the company's business ahead of a German reimbursement decision that is expected to finalize today.

In a note to investors, analyst William Quirk said that the company's stock has been off significantly since it announced its Q1 earnings, necessitating the rating upgrade to maintain the existing price target.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.